Bolt Biotherapeutics (BOLT) vs Lexaria Bioscience (LEXX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bolt Biotherapeutics is the larger company by market cap ($7.0 million vs $6.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | BOLT | LEXX |
|---|---|---|
| Share price | $3.65 | $3.20 |
| Market cap | $7.03M | $6.74M |
| 1-day change | +1.39% | -8.57% |
| EPS (TTM) | $-16.51 | $-5.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.20 | $21.60 |
| 52-week low | $3.10 | $2.77 |
| Distance from 52-week high | -49.31% | -85.19% |
| Average volume | 26.19K | 62.08K |
| Shares outstanding | 1.93M | 2.11M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
BOLT vs LEXX FAQ
Which is bigger, Bolt Biotherapeutics or Lexaria Bioscience?
Bolt Biotherapeutics (BOLT) is larger, with a market capitalization of $7.03M compared with $6.74M for Lexaria Bioscience (LEXX).
Are Bolt Biotherapeutics and Lexaria Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.